David Chism, MD: For pairing it with the immunotherapy, I would prefer just 1 chemotherapy rather than ...

Cancer care for younger adults emphasizes emotional well-being and multidisciplinary support, transforming treatment ...

The FDA has approved the Guardant 360 CDx as a companion diagnostic to identify ESR1 mutation in patients with advanced ...

Explore the latest advancements in muscle-invasive bladder cancer treatment, including immunotherapy and novel therapies ...

In an interview with Targeted Oncology, Shane Dormady, MD, medical director of El Camino Health Cancer Center, highlights the unique challenges and differences in the priorities o ...

The IMFORTE trial represents a breakthrough for patients with ES-SCLC who complete initial treatment without disease progression, offering new hope through maintenance therapy wit ...

An expert discusses how the IMpower133 trial established atezolizumab plus chemotherapy as standard care for extensive-stage small cell lung cancer, improving overall survival from 10.3 to 12.3 months ...

An expert discusses the MARIPOSA study’s impact on managing central nervous system (CNS) involvement in EGFR-mutated non–small cell lung cancer, emphasizing improved brain progression-free survival, ...

The challenge of managing relapsed or refractory B-cell malignancies continues to thwart the efforts of oncologists and ...

The FDA has approved a new subcutaneous (SC) formulation of pembrolizumab (Keytruda Qlex), co-formulated with ...

When patients with advanced melanoma progress following treatment with immune checkpoint inhibitors (ICIs) and targeted ...

New findings reveal tarlatamab combined with anti–PD-L1 agents significantly improves survival in extensive-stage small cell ...